MAIA Biotechnology, Inc.
June 18, 2025
Company Presentation
Oncology
153C
MAIA Biotechnology is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead candidate is Ateganosine (THIO), a novel telomere-targeting agent currently in clinical development.
Company HQ City:
Chicago
Company HQ State:
IL
Company HQ Country:
United States
Year Founded:
2018
Lead Product in Development:
Ateganosine (THIO)
CEO
Vlad Vitoc
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
1
Exchange
NYSE
Ticker
MAIA
When you expect your next catalyst update?
Start of expansion of Phase 2 trial and start of Phase 3 trial.
What is your next catalyst (value inflection) update?
Start of expansion of Phase 2 trial in end of April/May; and start of Phase 3 trial in H2 2025.
Website
https://maiabiotech.com/
)
)
){kind=logo}
){kind=logo}
){kind=logo}